OSL : Follow-up

Since my last post on OSL (ASX : OSL), I’ve had a few interesting reach-outs confirming my viewpoint on this company and also providing a bit more “colour”. I should note that all of this information is actually reasonably consistent with the discussion I had with Daniel Kenny (CEO) last week, with one exception and I…

The VLA Coin Toss

“It is not a case of choosing those [faces] that, to the best of one’s judgment, are really the prettiest, nor even those that average opinion genuinely thinks the prettiest. We have reached the third degree where we devote our intelligences to anticipating what average opinion expects the average opinion to be. And there are…

Imugene’s Monster Raise

Following last week’s ASX trading halt request, I have been waiting for the announcement regarding Imugene’s (ASX : IMU) financing. The news came at market open this morning, specifically that the company had placed $3m through the “usual suspects”. Combined with the end-year disclosure, this means the company has about $5m in the bank +/- 10% with a…

The Questionable Ethics of Anisina – Part II

I have lost a lot of sleep this week about my prior post on the relationship between Novogen/Anisina (ASX : NRT) and the Kids’ Cancer Project. I received some fairly scathing emails from donors who are obviously very passionate about what the Kids’ Cancer Project represents and – if I am honest with you –…